文献速递临床试验与 GCP真实世界研究与卫生经济

钾补充与心脏手术后心房颤动的预防:TIGHT K 随机临床试验

Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

这项在 23 个中心开展的非劣效性随机试验纳入 1690 例拟行单纯冠状动脉旁路移植术且无房性心律失常史的患者,比较宽松补钾阈值(低于 3.6 mEq/L 才补)与严格补钾阈值(低于 4.5 mEq/L 即补)。宽松组主要终点发生率为 27.8%,严格组为 26.2%,风险差 1.7%(95%CI -2.6% 至 5.9%),达到非劣效;宽松组每人补钾成本显著更低。

要点

  • 宽松补钾(低于 3.6 mEq/L 才补)对术后房颤预防非劣于严格补钾(低于 4.5 mEq/L 即补)。
  • 风险差 1.7%(95%CI -2.6% 至 5.9%),上限低于预设的 10% 非劣效界值。
  • 宽松组每人补钾成本平均低 111.89 美元(95%CI 103.60-120.19 美元;P<.001)。

核心结论

  • 对于心脏手术后心房颤动预防,仅在血清钾浓度低于 3.6 mEq/L 时补钾,非劣于当前广泛采用的维持血清钾浓度大于或等于 4.5 mEq/L 的补钾做法。
  • 较低补钾阈值与心律失常或不良临床结局增加无关。

研究设计与样本

  • 开放标签、非劣效性随机临床试验,在英国和德国的 23 个心脏外科中心开展。
  • 2020年10月20日至2023年11月16日纳入无房性心律失常史、拟行单纯冠状动脉旁路移植术的患者,末例患者于2023年12月11日出院。
  • 患者随机分配至严格补钾策略(血清钾低于 4.5 mEq/L 才补)或宽松补钾策略(血清钾低于 3.6 mEq/L 才补)。
  • 患者佩戴动态心律监测仪,由对分组设盲的核心实验室分析。
  • 共 1690 例患者随机(平均年龄 65 岁;女性 256 例,占 15%)。

主要发现

  • 主要终点在严格组发生率为 26.2%(n=219),宽松组为 27.8%(n=231),风险差 1.7%(95%CI -2.6% 至 5.9%)。
  • 两组在任何方式检测到的至少 1 次房颤发作、仅由动态心律监测仪检测到的房颤发作、非房颤性心律失常、住院死亡或住院时长方面无差异。
  • 宽松组每人购买和给予钾的成本显著更低(平均差 111.89 美元[95%CI 103.60-120.19 美元];P<.001)。

关键数值与推荐

  • 非劣效性定义为新发心脏手术后心房颤动的风险差单侧 97.5%CI 上限小于 10%。
  • 主要终点为冠状动脉旁路移植术后 120 小时内或出院前(以先发生者为准)临床检出并经心电图确认的新发心脏手术后心房颤动。
  • 所有主要结局事件由对分组设盲的事件验证委员会验证。

临床怎么用

  • 作者结论认为,仅在血清钾浓度低于 3.6 mEq/L 时补钾用于心脏手术后心房颤动预防非劣于维持血清钾大于或等于 4.5 mEq/L 的广泛做法。
  • 作者结论认为,较低补钾阈值与心律失常或不良临床结局增加无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Supplementing potassium in an effort to maintain high-normal serum concentrations is a widespread strategy used to prevent atrial fibrillation after cardiac surgery (AFACS), but is not evidence-based, carries risks, and is costly. OBJECTIVE: To determine whether a lower serum potassium concentration trigger for supplementation is noninferior to a high-normal trigger. DESIGN, SETTING, AND PARTICIPANTS: This open-label, noninferiority, randomized clinical trial was conducted at 23 cardiac surgical centers in the United Kingdom and Germany. Between October 20, 2020, and November 16, 2023, patients with no history of atrial dysrhythmias scheduled for isolated coronary artery bypass grafting (CABG) surgery were enrolled. The last study patient was discharged from the hospital on December 11, 2023. INTERVENTIONS: Patients were randomly assigned to a strategy of tight or relaxed potassium control (only supplementing if serum potassium concentration fell below 4.5 mEq/L or 3.6 mEq/L, respectively). Patients wore an ambulatory heart rhythm monitor, which was analyzed by a core laboratory masked to treatment assignment. MAIN OUTCOMES AND MEASURES: The prespecified primary end point was clinically detected and electrocardiographically confirmed new-onset AFACS in the first 120 hours after CABG surgery or until hospital discharge, whichever occurred first. All primary outcome events were validated by an event validation committee, which was masked to treatment assignment. Noninferiority of relaxed potassium control was defined as a risk difference for new-onset AFACS with associated upper bound of a 1-sided 97.5% CI of less than 10%. Secondary outcomes included other heart rhythm-related events, clinical outcomes, and cost related to the intervention. RESULTS: A total of 1690 patients (mean age, 65 years; 256 [15%] females) were randomized. The primary end point occurred in 26.2% of patients (n = 219) in the tight group and 27.8% of patients (n = 231) in the relaxed group, which is a risk difference of 1.7% (95% CI, -2.6% to 5.9%). There was no difference between the groups in the incidence of at least 1 AFACS episode detected by any means or by ambulatory heart rhythm monitor alone, non-AFACS dysrhythmias, in-patient mortality, or length of stay. Per-patient cost for purchasing and administering potassium was significantly lower in the relaxed group (mean difference, $111.89 [95% CI, $103.60-$120.19]; P <.001). CONCLUSIONS AND RELEVANCE: For AFACS prophylaxis, supplementation only when serum potassium concentration fell below 3.6 mEq/L was noninferior to the current widespread practice of supplementing potassium to maintain a serum potassium concentration greater than or equal to 4.5 mEq/L. The lower threshold of supplementation was not associated with any increase in dysrhythmias or adverse clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04053816.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. O'Brien B, Campbell NG, Allen E, et al. Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial. JAMA. 2024. PMID: 39215972. doi:10.1001/jama.2024.17888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。